Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
SONIRE Therapeutics Inc.
Age
20–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Ages 20 years and over.
Unresectable pancreatic cancer (including metastatic pancreatic cancer) who are refractory or intolerant to first-line chemotherapy. Any first-line chemotherapy is acceptable.
Target treatment tumor is located in the pancreas, and the target tumor can be visualized with ultrasound echography and can also be treated by high-intensity focused ultrasound.
Has primary tumor site of measurable lesion according to RECIST guidelines version 1.1
ECOG performance status of 0 to 2.
You may not be if
Active multiple cancers that require treatment.
Suspected gastrointestinal invasion of the primary tumor based on CT scan.
Obstructive jaundice. However, patients who have a bile duct stent placed for obstructive jaundice by the time of allocation may be enrolled.
Child-Pugh Classification B or C liver failure due to liver metastases.
Tumor embolization in the veins surrounding the pancreas.
Cystic component within the pancreatic cancer.
Peritoneal dissemination.
Pleural effusion or ascites with poorly controlled
Contraindications to the use of secondary chemotherapy used in this study.
Clareo Health | A Study of Suizenji in Patients With Unresectable Pancreatic Cancer
